Clarivate's 'Drugs to Watch' Report Signals Obesity Therapies, China Innovation
Event summary
- Clarivate's 2026 'Drugs to Watch' report identifies 11 therapies with potential blockbuster status or transformative impact.
- The report highlights therapies targeting metabolic disease, oncology, immunology, rare conditions, and neurological disorders.
- Obesity drug sales are projected to reach USD 150 billion by 2035, driving focus on real-world effectiveness and payer considerations.
- Mainland China is increasingly recognized as both a significant commercial market and a source of pharmaceutical innovation.
The big picture
Clarivate's report underscores the intensifying competition within the pharmaceutical sector, driven by scientific advancements and evolving patient needs. The focus on therapies for metabolic disease, particularly obesity, reflects the growing prevalence of these conditions and the significant commercial opportunity they represent. The report also highlights the rising influence of China as a source of both market demand and innovative therapies, potentially reshaping global pharmaceutical strategies.
What we're watching
- Market Adoption
- The ability of these therapies, particularly those targeting obesity, to demonstrate real-world effectiveness and secure payer reimbursement will be critical for achieving blockbuster status, given the projected market size.
- China Competition
- The increasing competitiveness of therapies originating from Mainland China will likely pressure pricing and market share for established pharmaceutical companies globally.
- Delivery Innovation
- The success of oral delivery alternatives to injectable drugs will hinge on their ability to improve patient adherence and demonstrate superior clinical outcomes compared to existing treatments.
Related topics